Apellis(APLS) ZACKS·2025-02-21 16:00Core Viewpoint - Apellis Pharmaceuticals, Inc. (APLS) is anticipated to report a year-over-year increase in earnings driven by higher revenues for the quarter ending December 2024, with the actual results being crucial for its near-term stock price movement [1][2]. Earnings Expectations - The earnings report is scheduled for release on February 28, 2025, and could lead to a stock price increase if the results exceed expectations, while missing estimates may result in a decline [2]. - The consensus estimate indicates a quarterly loss of 195.95 million, a 33.9% increase from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 1.77% higher, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Apellis is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -12.56%, suggesting a bearish outlook from analysts [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict deviations from consensus estimates, with a positive reading being a strong indicator of an earnings beat, especially when combined with a favorable Zacks Rank [6][8]. - Apellis currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [11]. Historical Performance - In the last reported quarter, Apellis was expected to post a loss of 0.46, resulting in a surprise of -43.75% [12]. - Over the past four quarters, the company has only surpassed consensus EPS estimates once [13]. Industry Comparison - Beam Therapeutics Inc. (BEAM), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to report a loss of 20.86 million [17]. - Beam Therapeutics has an Earnings ESP of -0.39% and a Zacks Rank of 2, making it similarly difficult to predict an earnings beat [18].